D. Polhamus

发表

Clinical Trial Simulation in Alzheimer’s Disease

Diane Stephenson, Klaus Romero, Kaori Ito, 2014 .

Population pharmacokinetics and exposure–response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2‐targeted regimens

Jin Y. Jin, S. Girish, Shang-Chiung Chen, 2017, British journal of clinical pharmacology.

Modeling and simulation of the exposure–response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD

M. Gastonguay, W. Knebel, D. Polhamus, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

Jin Y. Jin, S. Girish, Shang-Chiung Chen, 2019, Cancer Chemotherapy and Pharmacology.

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

Klaus Romero, Marc R. Gastonguay, William R. Gillespie, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Drug Development for Neurodegenerative Diseases Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating

C. Compton, M. Carrillo, B. Corrigan, 2014 .

Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases

C. Jack, C. Compton, M. Carrillo, 2013, Therapeutic innovation & regulatory science.

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus

B. Monz, J. Gross, A. Staab, 2013, BMJ Open.

P490 A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis

N. Dirks, D. Polhamus, M. Rosario, 2019, Journal of Crohn's and Colitis.

P529 Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1

G. D'Haens, W. Sandborn, B. Feagan, 2019, Journal of Crohn's and Colitis.

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

K. Koblan, G. Galluppi, S. Hopkins, 2021, CPT: pharmacometrics & systems pharmacology.

Modeling and simulation of the exposure–response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD

M. Gastonguay, W. Knebel, D. Polhamus, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

The future is now: Model‐based clinical trial design for Alzheimer's disease

D Polhamus, L. Pani, B. Corrigan, 2015, Clinical pharmacology and therapeutics.

Longitudinal Exposure—Response Modeling of Multiple Indicators of Alzheimer’s Disease Progression

L. Honigberg, M. Dolton, J. Rogers, 2023, The Journal of Prevention of Alzheimer's Disease.

Technical Appendix to : A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications : an example using DPP-4 inhibitors , sitagliptin and linagliptin , in treatment of type 2 diabetes mellitus December

B. Monz, J. Gross, A. Staab, 2012 .

Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

S. Girish, Shang-Chiung Chen, A. Joshi, 2017, Cancer Chemotherapy and Pharmacology.

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

Kaori Ito, B. Corrigan, K. Romero, 2012, Journal of Pharmacokinetics and Pharmacodynamics.